Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Nov 23;7:16106. doi: 10.1038/s41598-017-16293-6

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2017

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Effects of Intralipid treatment on the tumor growth and the anti-tumor efficacy of DACHPt/HANP as well as the survival rate in a HT-29 xenograft tumor model. (A) Treatment protocol. (B) Survival rate of HT-29 bearing BALB/c nude mice for the four treatment groups. (C) Changes of the tumor size upon treatment with vehicle, Intralipid alone, and DACHPt/HANP at 2 mg Pt/kg with or without Intralipid administration. H&E staining of the bone marrow is shown in (D–K). (D,E) DACHPt/HANP treatment, with no Intralipid, causes moderate/severe depletion of erythroid and myeloid precursor cells in the bone marrow. (F,G) Intralipid treatment significantly reduces this damage. (H,I) and (J,K) Bone marrow from (i) vehicle-treated, and (ii) Intralipid alone group.